IKCS 2023: Exploring Unmet Needs and Novel Advances in Metastatic Kidney Cancer Care

Katy Beckermann, MD, PhD

November 15, 2023

Katy Beckermann, MD, PhD, after attending the 2023 International Kidney Cancer Symposium, highlights the conference's value in providing an intimate setting for discussions among colleagues about unmet needs and upcoming developments in kidney cancer care. Dr Beckermann notes the promising data presented by Dr Sumanta Kumar Pal on the new tyrosine kinase inhibitor zanzalintinib, in an early-phase clinical trial for refractory kidney cancer, as a novel opportunity for patients.

Dr Beckermann also notes IKCS' unique emphasis on fostering discussions among diverse care partners, such as urologists and radiation oncologists, in addressing unmet needs in a collaborative manner.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: IKCS 2023: Exploring Unmet Needs and Novel Advances in Metastatic Kidney Cancer Care - Medscape - Nov 15, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.